Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Lipoprotein(a) [Lp(a)] is a significant, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS).
• Elevated Lp(a) impacts roughly 20% of the global population, yet effective pharmacological treatments have been lacking, creating a gap in residual cardiovascular risk management.

Purpose of the Study:

• To synthesize current knowledge on Lp(a) structure, genetics, and metabolism.
• To review mechanistic links between Lp(a) and cardiovascular disease pathways.
• To provide an overview of emerging Lp(a)-targeted therapies and their implications for precision cardiovascular prevention.

Main Methods:

• Literature review synthesizing data on Lp(a) molecular architecture, genetics, and metabolism.
• Integration of mechanistic evidence linking Lp(a) to pro-atherogenic, pro-inflammatory, and pro-thrombotic pathways.
• Summary of epidemiological and genetic data associating Lp(a) with cardiovascular outcomes.
• Overview of current clinical guidelines for Lp(a) screening and risk stratification.
• Review of emerging therapeutic strategies, including RNA-targeted therapies and small molecules.

Main Results:

• Lp(a) is mechanistically linked to key pathways driving atherosclerosis, inflammation, and thrombosis.
• Epidemiological and genetic data strongly associate elevated Lp(a) with diverse cardiovascular outcomes.
• A new wave of therapies, including RNA-targeted and small molecule drugs, are in late-stage development to target Lp(a).

Conclusions:

• The field is moving towards treating Lp(a) as an actionable therapeutic target, not just a biomarker.
• Emerging therapies hold promise for improving residual risk management in ASCVD and CAVS.
• Targeting Lp(a) represents a significant advancement in precision cardiovascular prevention strategies.